Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome plus cisplatin/carboplatin for gastrointestinal and pancreatic neuroendocrine carcinoma
ChiCTR2400086534Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jul 2024
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of irinotecan liposome in apudoma (NET), neuroendocrine carcinoma (NEC), gastrointestinal neuroendocrine tumor and 1 more, sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Objective response rate. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
irinotecan liposome
03
Conditions
apudoma (NET)neuroendocrine carcinoma (NEC)gastrointestinal neuroendocrine tumorislet cell tumor
Beyond the preview
Go deeper on ChiCTR2400086534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086534.